Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Myelodysplastic Syndromes 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Myeloproliferative Disorders 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Graft vs Host Disease 3Waldenstrom Macroglobulinemia 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Burkitt Lymphoma 2Breast Neoplasms 2Brain Neoplasms 2Anemia, Aplastic 2Thrombocythemia, Essential 1Skin Neoplasms 1Sezary Syndrome 1Sarcoma, Myeloid 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdoid Tumor 1Recurrence 1Primary Myelofibrosis 1

Interventions

temsirolimus 1Vorinostat 1Sirolimus 1Everolimus 1Clinical Trials, Phase IV as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Advanced Cancer × Sirolimus × Clear all
NCT01087554 2026-01-16

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
249 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡